GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...
Officials in Brazil’s well-regarded public health system are scrambling to explain this week how six transplant patients ...
News Medical on MSN5d
Exclusion of indigenous voices hinders HIV progress in Latin AmericaIndigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...
In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...
The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...
People with HIV are more likely to have severe premenstrual syndrome (PMS) symptoms than others, such as: In the United States, about 2% of transgender people make up new HIV diagnoses.
Daily Maverick on MSN17h
New leadership at South Africa’s National Aids Council has a bold vision for HIV advocacyHIV activist Solly Nduku was recently elected to the top civil society position at the South African National Aids Council.
Uganda's efforts to combat the HIV/AIDS epidemic have made significant strides, yet crucial gaps remain, particularly in preventing mother-to-child transmission of the virus.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback